101 related articles for article (PubMed ID: 2834838)
1. Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes.
Whiteside TL; Heo DS; Takagi S; Herberman RB
Transplant Proc; 1988 Apr; 20(2):347-50. PubMed ID: 2834838
[TBL] [Abstract][Full Text] [Related]
2. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
3. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
5. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2.
Whiteside TL; Heo DS; Takagi S; Johnson JT; Iwatsuki S; Herberman RB
Cancer Immunol Immunother; 1988; 26(1):1-10. PubMed ID: 3257898
[TBL] [Abstract][Full Text] [Related]
7. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor effector cells in recombinant IL-2 activated tumor infiltrating lymphocytes from human solid cancers].
Ishii S; Shiiba K; Ebina N; Matsuno S
Nihon Geka Gakkai Zasshi; 1993 Mar; 94(3):213-24. PubMed ID: 7686244
[TBL] [Abstract][Full Text] [Related]
9. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
Miescher S; Whiteside TL; Moretta L; von Fliedner V
J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
Xu ZY
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
[TBL] [Abstract][Full Text] [Related]
12. Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2.
Takagi S; Chen K; Schwarz R; Iwatsuki S; Herberman RB; Whiteside TL
Cancer; 1989 Jan; 63(1):102-11. PubMed ID: 2642728
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
14. [The relationship between TIL from human primary hepatic carcinoma and prognosis].
Qin J; Han B; Pang J
Zhonghua Yi Xue Za Zhi; 1997 Mar; 77(3):167-70. PubMed ID: 9596951
[TBL] [Abstract][Full Text] [Related]
15. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
16. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
[TBL] [Abstract][Full Text] [Related]
17. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
18. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2.
Sawamura Y; Hosokawa M; Kuppner MC; Kobayashi H; Aida T; Abe H; de Tribolet N
Cancer Res; 1989 Apr; 49(7):1843-9. PubMed ID: 2784352
[TBL] [Abstract][Full Text] [Related]
20. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex.
Schoof DD; Selleck CM; Massaro AF; Jung SE; Eberlein TJ
Cancer Res; 1990 Feb; 50(4):1138-43. PubMed ID: 2137027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
